Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.51 USD
Change Today +0.13 / 1.76%
Volume 175.8K
STAA On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

staar surgical co (STAA) Snapshot

Open
$7.44
Previous Close
$7.38
Day High
$7.58
Day Low
$7.33
52 Week High
04/23/14 - $19.74
52 Week Low
01/27/15 - $4.84
Market Cap
291.4M
Average Volume 10 Days
218.8K
EPS TTM
$-0.21
Shares Outstanding
38.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STAAR SURGICAL CO (STAA)

Related News

No related news articles were found.

staar surgical co (STAA) Related Businessweek News

No Related Businessweek News Found

staar surgical co (STAA) Details

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company offers implantable collamer lenses (ICL) comprising Visian ICL to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also provides invasive intraocular lenses (IOL) that include aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece collamer aspheric optic; Toric IOL for cataract patients to treat pre-existing astigmatism; and Preloaded Injector, a silicone or acrylic IOL preloaded into a single-use disposable injector. In addition, the company sells surgical products, and other related instruments and devices; and manufactures AquaFlow device for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health maintenance organizations, group purchasing organizations, and government facilities. The company offers its products primarily under the STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow names. It sells products directly through its sales representatives in the United States, Canada, Japan, and Spain, as well as through independent distributors in approximately 60 countries worldwide. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

300 Employees
Last Reported Date: 03/13/15
Founded in 1982

staar surgical co (STAA) Top Compensated Officers

Chief Financial Officer and Vice President
Total Annual Compensation: $122.0K
Vice President, Corporate Compliance Officer,...
Total Annual Compensation: $377.4K
Chief Accounting Officer and Vice President
Total Annual Compensation: $334.4K
Vice President of Global Research & Developme...
Total Annual Compensation: $366.7K
Vice President of Global Marketing
Total Annual Compensation: $324.6K
Compensation as of Fiscal Year 2013.

staar surgical co (STAA) Key Developments

STAAR Surgical Company Announces Executive Changes

STAAR Surgical Company has named Caren Mason as President and Chief Executive Officer effective immediately. Ms. Mason, who was elected to STAAR's Board of Directors in June 2014, and was appointed by the Board to chair the Quality and Regulatory Committee in September 2014, replaces Barry G. Caldwell who retired as of March 1, 2015. Ms. Mason joins STAAR after most recently serving as CEO of, and then advisor to, Verinta Health. Previously, she served as President & CEO of publicly traded Quidel Corporation between 2004 and 2009.

STAAR Surgical Company Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Fiscal Year Ended January 2, 2015

STAAR Surgical Company reported unaudited consolidated earnings results for the fourth quarter and fiscal year ended January 2, 2015. For the quarter, sales were $16.6 million compared with $18.9 million for the fourth quarter of 2013. The GAAP net loss was $2.5 million or $0.07 on a per diluted share basis, compared with a net loss of $876,000 or $0.02 on a per diluted share basis, in the fourth quarter of 2013. Adjusted net loss (excluding manufacturing consolidation expenses for the prior year's quarter, gain (loss) on foreign currency transactions, stock-based compensation expense and FDA panel and remediation expenses) was $1.2 million or $0.03 per diluted share versus adjusted net income for the prior year's quarter of $850,000 or $0.02 per diluted share. Operating income was $3.74 million compared to $1.25 million a year ago. Loss before provision (benefit) for income taxes was $3.93 million compared to $1.05 million a year ago. During the quarter, the company used $3.5 million in cash for operating activities and $1.5 million for the purchase of property and equipment. For the fiscal year, the company reported net sales of $74.99 million an increase of 4% compared to $72.22 million for the fiscal year 2013 and increased 6% on a constant currency basis. The GAAP net loss was $8.4 million or $0.22 on a per diluted share basis, compared to net income of $398,000 or $0.01 on a per diluted share basis for the prior year. Adjusted net income was $779,000 or $0.02 per diluted share versus adjusted net income of $7.5 million or $0.19 per diluted share for the prior year. Operating loss was $8.03 million compared to operating income of $0.700 million a year ago. Loss before provision (benefit) for income taxes was $8.65 million compared to income before provision (benefit) for income taxes of $1.11 million a year ago. Net cash used in operating activities was $7.95 million compared to net cash provided by operating activities of $3.36 million a year ago. Acquisition of property and equipment was $4.05 million compared to $3.45 million a year ago.

STAAR Surgical Company to Report Q4, 2014 Results on Feb 25, 2015

STAAR Surgical Company announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STAA:US $7.51 USD +0.13

STAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.62 USD +0.04
Biolase Inc $2.00 USD 0.00
Cerus Corp $4.23 USD +0.13
Cutera Inc $12.97 USD -0.26
SurModics Inc $26.00 USD +0.04
View Industry Companies
 

Industry Analysis

STAA

Industry Average

Valuation STAA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STAAR SURGICAL CO, please visit www.staar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.